Anders Elias Hansen

Anders Elias Hansen

Auto-generated profile, based on publicly available information

Anders Elias Hansen

Section for Cell and Drug Technologies, Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2015 in ACS Nano
Verified
Journal Article
Closed access
AHAnders E. Hansen
Anders E. Hansen
APAnncatrine L. Petersen
Anncatrine L. Petersen
JHJonas R. Henriksen
Jonas R. Henriksen
BBBetina Boerresen
Betina Boerresen
PRPalle Rasmussen
Palle Rasmussen
TAThomas L. Andresen
Thomas L. Andresen

1 October 2012 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
APAnncatrine L. Petersen
Anncatrine L. Petersen
AHAnders E. Hansen
Anders E. Hansen
AGAlberto Gabizon
Alberto Gabizon
TAThomas L. Andresen
Thomas L. Andresen

31 March 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JCJorge Peiró Cadahía
Jorge Peiró Cadahía
JBJon Bondebjerg
Jon Bondebjerg
CHChristian A. Hansen
Christian A. Hansen
VPViola Previtali
Viola Previtali
AHAnders E. Hansen
Anders E. Hansen
MCMads Clausen
Mads Clausen

26 October 2010 in Veterinary Radiology & Ultrasound
Verified
Journal Article
Closed access
PDF file
AHAnders E. Hansen
Anders E. Hansen
FMFintan Mcevoy
Fintan Mcevoy
SESvend A. Engelholm
Svend A. Engelholm
ILIan Law
Ian Law
AKAnnemarie T. Kristensen
Annemarie T. Kristensen

1 February 2022 in Journal of Controlled Release
Verified
Journal Article
Closed access
CSCamilla Stavnsbjerg
Camilla Stavnsbjerg
ECEsben Christensen
Esben Christensen
RMRasmus Münter
Rasmus Münter
JHJonas R. Henriksen
Jonas R. Henriksen
MFMatthias Fach
Matthias Fach
TAThomas L. Andresen
Thomas L. Andresen

4 September 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
LRL. Ringgaard
L. Ringgaard
FMF. Melander
F. Melander
RER. Eliasen
R. Eliasen
JHJ. R. Henriksen
J. R. Henriksen
RJR. I. Jølck
R. I. Jølck
TAT. L. Andresen
T. L. Andresen
Immunosuppressive cells in the tumor microenvironment allow cancer cells to escape immune recognition and support cancer progression and dissemination. To improve therapeutic efficacy, we designed a liposomal oxaliplatin formulation (PCL8-U75) that elicits cytotoxic effects toward both cancer and immunosuppressive cells via protease-mediated, intratumoral liposome activation. The PCL8-U75 liposomes displayed superior therapeutic efficacy across all syngeneic cancer models in comparison to free-drug and liposomal controls. The PCL8-U75 depleted myeloid-derived suppressor cells and tumor-associated macrophages in the tumor microenvironment. The combination of improved cancer cell cytotoxicity and depletion of immunosuppressive populations of immune cells is attractive for combination with immune-activating therapy. Combining the PCL8-U75 liposomes with a TLR7 agonist induced immunological rejection of established tumors. This combination therapy increased intratumoral numbers of cancer antigen–specific cytotoxic T cells and Foxp3− T helper cells. These results are encouraging toward advancing liposomal drug delivery systems with anticancer and immune-modulating properties into clinical cancer therapy.